Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome

Mu, Liangshan; Pan, Jiexue; Yang, Lili; Chen, Qianqian; Chen, Ya; Teng, Yili; Wang, Peiyu; Tang, Rong; Huang, Xuefeng; Xia, Chen; Yang, Haisong

doi:10.1186/s12958-018-0419-x

Cited by 50 publications

(61 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown increasing SUA levels were positively associated with increased cardiovascular mortality and increased the risk of adverse pregnancy outcomes in PCOS patients, therefore SUA level determination is valuable for women with PCOS [15,25]. Several studies had reported that the SUA levels and prevalence of hyperuricemia increased greatly in obese PCOS women [13], which was similar to present results. However, the underlying mechanism had not been clear until now, there were some hypotheses as following: body fat accelerated SUA production and the synthesis of triglyceride [26] and hyperinsulinemia could decrease renal UA excretion [27].…”

Section: Discussionsupporting

confidence: 90%

“…Hyperuricemia is a disease of impaired uric acid metabolism. A recent study indicated that the prevalence of hyperuricemia in PCOS women is more than 25%, while 58.75% of obese PCOS women approximately suffer from hyperuricemia, which was almost three folds higher than that in PCOS women with normal BMI [13]. Elevated SUA level not only increased the risk of gout, but also increased cardiovascular risk by promoting in ammation, oxidative stress and proliferation in PCOS women [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Visceral adiposity index was independently associated with hyperuricemia in patients with polycystic ovary syndrome

Chen

Yan

Yang

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: The current study aimed to explore the prevalence rate of hyperuricemia in women with polycystic ovary syndrome (PCOS) and investigate the relationship between Visceral adiposity index (VAI) and hyperuricemia in PCOS.Methods: In this cross-sectional study, 318 PCOS women were evaluated between November 2018 to September 2020. Of them, 256 subjects with complete anthropometric and the serum uric acid (SUA) level data were analyzed. Multivariable linear regression and logistic regression analyses were performed to determine the associations of VAI with the SUA level and hyperuricemia.Results: The prevalence rate of hyperuricemia was 56.3% in women with PCOS and was gradually increased across tertiles of VAI, which was 2.6%, 21.3%, 22.4%, respectively. Obese subjects had significantly higher levels of systolic blood pressure (SBP), waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR), body fat percentage (BFP), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), VAI (P<0.001) and lower high-density lipoprotein cholesterol (HDL-c) (P<0.001). Pearson correlation analysis showed the SUA level was positively correlated with BMI, BFP, WHR, log (TG), log (LDL-c), SBP, and log (VAI) and negatively correlated with HDL-c. In addition, with adjustment for potential confounding factors, multivariable linear regression and logistic regression analyses showed that VAI significantly associated with the SUA level and hyperuricemia, with the coefficient (95% confidence interval (CI)) of 9.20 (2.85-15.56, P=0.005) and the adjusted odds ratio (95% CI) of 1.32 (1.05-1.65, P=0.018), respectively.Conclusion: The present study indicates that VAI was independently associated with hyperuricemia, even with adjustment for BMI and other potential confounding factors.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Visceral adiposity index was independently associated with hyperuricemia in patients with polycystic ovary syndrome

Chen

Yan

Yang

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown increasing SUA levels were positively associated with increased cardiovascular mortality and increased the risk of adverse pregnancy outcomes in PCOS patients, therefore SUA level determination is valuable for women with PCOS [15,25]. Several studies had reported that the SUA levels and prevalence of hyperuricemia increased greatly in obese PCOS women [13], which was similar to our results. However, the underlying mechanism had not been clear until now, there were some hypotheses as following: body fat accelerated SUA production and the synthesis of triglyceride [26] and hyperinsulinemia could decrease renal UA excretion [27].…”

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Visceral Adiposity Index was Independently Associated with Hyperuricemia in Patients with Polycystic Ovary Syndrome

Chen

Yan

Yang

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: The current study aimed to explore the prevalence rate of hyperuricemia in women with polycystic ovary syndrome (PCOS) and investigate the relationship between Visceral adiposity index (VAI) and hyperuricemia in PCOS.Methods: In this cross-sectional study, 318 PCOS women were evaluated between November 2018 to September 2020. Of them, 256 subjects with complete anthropometric and SUA data were analyzed. Multivariable linear regression and logistic regression analyses were performed to determine the associations of VAI with the SUA level and hyperuricemia.Results: The prevalence rate of hyperuricemia was 56.3% in women with PCOS and was gradually increased across tertiles of VAI, which was 2.6%, 21.3%, 22.4%, respectively. Obese subjects had significantly higher levels of systolic blood pressure (SBP), waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR), body fat percentage (BFP), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), VAI (P<0.001) and lower high-density lipoprotein cholesterol (HDL-c) (P<0.001). Pearson correlation analysis showed the SUA level was positively correlated with BMI, BFP, WHR, log (TG), log (LDL-c), SBP, and log (VAI) and negatively correlated with HDL-c. In addition, with adjustment for potential confounding factors, multivariable linear regression and logistic regression analyses showed that VAI significantly associated with the SUA level and hyperuricemia, with the coefficient (95% confidence interval (CI)) of 9.20 (2.85-15.56, P=0.005) and the adjusted odds ratio (95% CI) of 1.32 (1.05-1.65, P=0.018), respectively.Conclusion: The present study indicates that VAI was independently associated with hyperuricemia, even with adjustment for BMI and other potential confounding factors.

show abstract

“…Urate is the product of purine metabolism and is mainly produced in the liver. Clinical studies have shown that urate is related to many hormones in the body, including luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen(E 2 ), and thyroid hormone (TH) ( Mumford et al, 2013 ; Mu et al, 2018 ). Thus far, there have been conflicting reports concerning the relationship between thyroid hormone and serum urate.…”

Section: Introductionmentioning

confidence: 99%

Thyroid Hormone-Regulated Expression of Period2 Promotes Liver Urate Production

Rothenberg

Liang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The relationship between thyroid hormones and serum urate is unclear. Our aim is to analyze the correlation between uric acid and thyroid hormones in gout patients and to explore the effect and mechanism of triiodothyronine on liver uric acid production. Eighty men patients with gout were selected to analyze the correlation between blood urate and thyroid function-related hormone levels. Stepwise multiple linear regression was used to analyze factors affecting blood urate in patients with gout. Levels of urate in serum, liver, and cell culture supernatant were measured after triiodothyronine treatment. Purine levels (adenine, guanine, and hypoxanthine) were also measured. Expression levels of Period2 and nucleotide metabolism enzymes were analyzed after triiodothyronine treatment and Period2-shRNA lentivirus transduction. Chromatin immunoprecipitation was used to analyze the effects of triiodothyronine and thyroid hormone receptor-β on Period2 expression. The results showed that in patients FT3 influenced the serum urate level. Furthermore, urate level increased in mouse liver and cell culture supernatant following treatment with triiodothyronine. Purine levels in mouse liver increased, accompanied by upregulation of enzymes involved in nucleotide metabolism. These phenomena were reversed in Period2 knockout mice. Triiodothyronine promoted the binding of thyroid hormone receptor-β to the Period2 promoter and subsequent transcription of Period2. Triiodothyronine also enhanced nuclear expression of Sirt1, which synergistically enhanced Period2 expression. The study demonstrated that triiodothyronine is independently positively correlated with serum urate and liver uric acid production through Period2, providing novel insights into the purine metabolism underlying hyperuricemia/gout pathophysiology.

show abstract

Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome

Cited by 50 publications

References 35 publications

Visceral adiposity index was independently associated with hyperuricemia in patients with polycystic ovary syndrome

Visceral adiposity index was independently associated with hyperuricemia in patients with polycystic ovary syndrome

Visceral Adiposity Index was Independently Associated with Hyperuricemia in Patients with Polycystic Ovary Syndrome

Thyroid Hormone-Regulated Expression of Period2 Promotes Liver Urate Production

Contact Info

Product

Resources

About